David E Cohn

4PUBLICATIONS
48CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jan 21, 2025
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).

Husam A Alqaisi, David E Cohn, Jing-Yi Chern

|Oct 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.

Benoit You, Christopher Purdy, Larry J Copeland

|Jan 07, 2022
Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study.

Monica D Levine, Rachel Pearlman, Heather Hampel

|Oct 28, 2021
Prehabilitation for medically frail patients undergoing surgery for epithelial ovarian cancer: a cost-effectiveness analysis.

Jhalak Dholakia, David E Cohn, J Michael Straughn

Pageof 1

Frequent Collaborators

1 joint publications

Rachel Pearlman

1 joint publications

Heather Hampel

1 joint publications

David A Barrington

1 joint publications

Joseph P McElroy